David Avigan, M.D.
Dr. Avigan is Assistant Professor of Medicine, Harvard Medical School, aand Director of Hematological Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center and Dana Farber Harvard Cancer Center, Boston, MA.
Within the last 12 months Dr. Avigan reports research support from Genzyme and Berlex.
This activity is made possible by an unrestricted educational grant from .
Estimated time to complete:
Albert Einstein College of Medicine designates this enduring material for a maximum of 0.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
Upon completion of this Cyberounds®
, you should be able to:
- Identify the unique biological characteristics of AML in the elderly and their impact on response to therapy
- Discuss therapeutic trials in elderly patients with AML which examine the role of aggressive and low intensity chemotherapy
- Define the role of autologous and allogeneic hematopoietic transplantation in elderly patients with AML
- Discuss the role of novel agents as therapy for elderly patients with AML.